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Based on studies in animal models, parenteral immunization has become recognized as a potential vaccination strategy
against rotavirus. Using an adult mouse model, the effects of the saponin adjuvant QS-21 on protection against murine
rotavirus (strain EDIM) infection was determined following two intramuscular (i.m.) immunizations with purified EDIM
particles including triple-layered (tl) infectious particles, tl particles inactivated with psoralen/UV, and double-layered (dl)
inactivated particles. All three particles stimulated large serum rotavirus IgG responses and small amounts of serum
rotavirus IgA, but undetectable stool rotavirus IgA. Inclusion of QS-21 during immunization increased the serum responses
approximately 2- to 10-fold and also stimulated low levels of stool rotavirus IgA. Protection based on reduced shedding of
rotavirus following EDIM challenge was significant (P , 0.001) with each immunized group and was enhanced (P , 0.001)
by inclusion of QS-21 during immunization. Mice immunized with either live or inactivated tl particles and QS-21 were almost
fully protected. Furthermore, animals inoculated with dl particles and the adjuvant shed significantly (P 5 .02) less virus
following challenge than mice immunized with inactivated tl particles even though the latter induced measurable titers of
neutralizing antibody to EDIM. These results demonstrate significant protection against rotavirus following i.m. immunization
with both dl and tl EDIM particles which is consistently enhanced with QS-21. © 1998 Academic Press
INTRODUCTION
Rotavirus is the primary cause of severe diarrhea in
infants and young children worldwide. Several vaccine
candidates have been evaluated, all of which are live,
orally deliverable, attenuated rotaviruses. These vac-
cines are intended to mimic the route of infection and
subsequent protection associated with natural infection.
However, rotavirus vaccine candidates tested to date
have provided only partial protection, even against se-
vere rotavirus disease (DeMol et al., 1986; Christy et al.,
1988; Bernstein et al., 1991, 1995; Santosham et al., 1991;
Clark et al., 1995; Rennels et al., 1996; Lanata et al., 1996).
Therefore, improved vaccines are clearly needed.
To facilitate the development of such vaccines and, at
the same time, to gain an understanding of the mecha-
nisms of active immunity against rotaviruses, an adult
mouse model was developed in our laboratory (Ward et
al., 1990). Using this model, it was found that protection
after oral immunization with live homologous or heterol-
ogous rotaviruses correlated with titers of serum and
stool rotavirus IgA (McNeal et al., 1994; Feng et al., 1994),
but no correlation was found between rotavirus IgG or
serotype-specific neutralizing antibody titers and protec-
tion (Ward et al., 1992). Further, it has been shown using
genetically engineered, antibody deficient mice that
complete protection against subsequent rotavirus infec-
tion was dependent on the presence of antibody (Mc-
Neal et al., 1995; Franco and Greenberg, 1995). Finally, in
a study using a hybridoma back-pack mouse model, it
was found that protection from murine rotavirus chal-
lenge was obtained in mice inoculated with anti-VP6
IgA-secreting hybridoma cells, and no protection was
obtained with anti-VP6 IgG-secreting hybridomas (Burns
et al., 1996). Thus, induction of serum or mucosal rotavi-
rus IgA may be an important correlate of protection
against infection with this intestinal pathogen.
Because protection against rotavirus disease was in-
complete following oral immunization with candidate
vaccines, alternative methods of immunization are being
investigated. One method is parenteral immunization
with live or inactivated rotavirus particles. Using the adult
mouse model, we demonstrated that parenteral (i.e., in-
traperitoneal) immunization with live or UV-inactivated
rotaviruses stimulated protection against challenge with
the murine rotavirus strain EDIM (McNeal et al., 1992).
Although high titers of serum rotavirus IgG were induced,
little or no serum or stool rotavirus IgA was detected in
the immunized mice. This suggested that rotavirus IgG
rather than IgA may be the better correlate of protection
following parenteral immunization. Subsequently, Con-
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ner et al. (1993) observed that two intramuscular immu-
nizations of rabbits with live or formalin-inactivated sim-
ian rotavirus (strain SA11) provided complete protection
against infection with a rabbit rotavirus. Again, no intes-
tinal rotavirus IgA was found in the immunized rabbit, but
instead, protection correlated with the presence of intes-
tinal rotavirus IgG. Thus, in both studies of parenteral
immunization in animal models, protection was associ-
ated with the presence of rotavirus IgG rather than IgA.
The purpose of the present study was to determine
whether protection following parenteral immunization in
the adult mouse model could be enhanced by the addi-
tion of an adjuvant, and whether the adjuvant would
stimulate production of serum and intestinal rotavirus
IgA. The saponin QS-21, purified from the bark of the
Quillaja saponaria (Kensil et al., 1991), has been shown
to enhance antibody and cell mediated immune re-
sponses to a number of different antigens (Newman et
al., 1992; Hancock et al., 1995, 1996). QS-21 has also
been shown to modulate the isotype and even the IgG
class of the antibody response to an antigen (Karagouni
and Hadjipetrou-Kouvounakis, 1990; Kensil et al., 1991;
Kensil, 1996). Furthermore, QS-21 has been used in
phase 1 trials in humans (Livingston et al., 1994) and,
therefore, may be a candidate for use in human vaccines.
In this study, we determined whether the protection stim-
ulated by intramuscular immunization with either live or
inactivated purified EDIM virus particles could be en-
hanced by inclusion of QS-21.
RESULTS
Rotavirus particles used for immunization
Triple-layered (tl) EDIM virus particles purified by CsCl
gradient centrifugation had a final titer of 8.4 3 108
focus-forming units (FFU)/ml while the double-layered
(dl) EDIM particles obtained from the same CsCl gradi-
ent and subsequently treated with 10 mM EDTA before
being repurified in CsCl had a titer of 3 3 103 FFU/ml.
Based on protein concentrations in both preparations,
the infectivity of the tl particles was 105 times greater
than that of the dl particles. Following treatment with
UV/psoralen, neither preparation had detectable infec-
tious virus (i.e., ,102 FFU/ml). Both tl (live and inacti-
vated) and dl particles were analyzed by SDS–PAGE gel
electrophoresis (Fig. 1). The tl particles contained the
known structural proteins VP1, VP2, VP3, VP4, VP6, and
VP7 while outer capsid proteins VP4 and VP7 were
undetectable in dl particles.
Antibody responses following immunization
BALB/c mice were immunized by two i.m. injections
with 20 mg of one of the three preparations of purified
EDIM particles described above either with or without
QS-21. Serum and stool samples collected 4 weeks after
the second immunization but prior to challenge were
examined for the presence of rotavirus antibody. All im-
munized groups of mice had very large and consistent
serum rotavirus IgG responses (Table 1). Groups that
received QS-21 with the EDIM particles had approxi-
mately 10-fold (P , 0.001) higher titers of rotavirus IgG
than mice immunized with the same particles without
adjuvant. Modest amounts of serum rotavirus IgA were
also detected in each of the immunized groups (Table 1),
and inclusion of QS-21 with the viral particles also re-
sulted in significantly (P , 0.001) higher quantities of this
antibody. No detectable stool rotavirus IgA was found in
the groups immunized with the three different viral par-
ticles without QS-21 (Table 1). However, when QS-21 was
included with any of these particles, significant (P ,
0.001) levels of rotavirus stool IgA were detected. Thus,
use of QS-21 as an adjuvant induced mucosal (intestinal)
IgA responses following intramuscular inoculation.
Serum neutralizing antibody against EDIM was also
found in all groups of mice immunized with the tl parti-
cles (Table 1). Infectious tl particles induced significantly
(P , 0.001) more neutralizing antibody compared to
inactivated particles. When QS-21 was included with the
infectious particles, significantly (P , 0.001) more neu-
tralizing antibody was induced. A small but insignificant
(P 5 0.09) increase in neutralizing antibody was also
induced by inclusion of QS-21 with the inactivated tl
particles. No neutralizing antibody was found in mice
FIG. 1. SDS–polyacrylamide gel electrophoresis of purified EDIM
particles. The rotavirus particles were purified as described under
Materials and Methods and their proteins were dissociated and sep-
arated by electrophoresis in SDS–polyacrylamide gels. Protein bands
were visualized by staining with Coomassie brilliant blue. Lane 1, 4
infectious tl EDIM particles; lane 2, 4 UV/psoralen inactivated tl parti-
cles; lane 3, 4 psoralen/UV inactivated dl particles.
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inoculated with the inactivated dl particles (Table 1). This
was consistent with the finding that VP4 and VP7 were
not found after purification of these particles.
To further establish that VP4 and VP7 proteins were
not present on dl particles, sera from mice immunized
with the three different preparations of EDIM particles
were used to immunoprecipitate 35S-labeled EDIM pro-
teins from infected cell lysates (Fig. 2). Antibodies
against both structural and nonstructural rotavirus pro-
teins were detectable in mice inoculated with infectious
tl particles. This result demonstrates that at least limited
replication of EDIM occurred following i.m. inoculation.
Sera from mice inoculated with inactivated tl particles
immunoprecipitated structural proteins but not the non-
structural proteins, further establishing that these viral
particles were inactivated. The serum from animals im-
munized with the dl particles also precipitated structural
proteins other than VP4 and VP7. The faint but detectable
protein band immunoprecipitated with this serum that
was observed at the position of VP7 was also found in
comparable amounts after immunoprecipitation of the
35S-labeled uninfected cell lysate (Fig. 2). These results
support previous evidence that dl particles were free of
the two outer capsid proteins.
As previously noted, the specific infectivity of purified
tl particles before UV/psoralen treatment was 105 times
greater than that of purified dl particles. Since the pres-
ence of the outer capsid VP4 and VP7 proteins is gen-
erally considered to be required for rotavirus infectivity,
the small amount of residual infectivity in the dl particle
preparation suggested that small quantities of VP4 and
VP7 may still be present. However, it was also possible
TABLE 1
Geometric Mean Titers of Rotavirus Antibodies in Mice at the Time of EDIM Challengea
Group
Serum IgG
(range)
Serum IgA
(range)
Stool IgA
(range)
Neutralizing
antibody
(range)
Unimmunized control ,100 ,100 ,5 ,20
(,100) (,100) (,5) (,20)
Triple-layered EDIM 1,570,375 414 ,5 330b
(1,022,800–2,694,000) (271–606) (,5) (248–524)
Triple-layered EDIM 1QS-21 12,898,880c 785c 134c 1021c
(9,816,000–13,296,000) (543–934) (64–390) (640–1,560)
Inactivated triple-layered EDIM 1,206,889 332 ,5 62
(866,100–1,641,000) (183–617) (,5) (20–144)
Inactivated triple-layered EDIM 1QS-21 9,203,958c 897c 116c 283
(6,299,000–15,038,000) (652–1,171) (30–238) (22–2,440)
Inactivated double-layered EDIM 1,051,074 267 ,5 ,20
(734,900–1,517,000) (237–335) (,5) (,20)
Inactivated double-layered EDIM 1QS-21 10,572,660c
(9,305,000–12,626,000)
826c
(522–1,440)
246c
(61–622)
,20
(,20)
a Mice were immunized i.m. with 20 mg of viral particles with and without QS-21 on days 0 and 14. Blood and stool specimens collected 4 weeks
after the second immunization but prior to EDIM challenge were used for this analysis.
b Significantly (P , 0.001) greater than the group inoculated with inactivated tl particles.
c Significantly (P , 0.001) greater than the group without QS-21.
FIG. 2. SDS–polyacrylamide gel electrophoresis of 35S-labeled pro-
teins immunoprecipitated from EDIM-infected (lanes 1–3) or mock
infectious tl particles (lanes 1 and 4); inactivated tl particles (lanes 2
and 5); or inactivated dl particles (lanes 3 and 6). Structural (VP) and
nonstructural (NSP) protein assignments are based on their positions
relative to molecular weight markers as described by Estes (1996).
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that dl particles retain some limited infectivity without
VP4 and VP7. VP4 and VP7 are the rotavirus neutraliza-
tion proteins and antibodies to either can neutralize
rotavirus. Therefore, it was reasoned that if the dl parti-
cles retain some VP4 and VP7, their residual infectivity
should be neutralized by treatment with murine hyperim-
mune serum to tl EDIM particles. When tested, it was
found that such serum did, in fact, neutralize this residual
infectivity (results not shown). However, this hyperim-
mune serum would also contain large quantities of anti-
VP6 antibody which may have been responsible for dl
particle neutralization. To determine if antibodies to VP6
could have this specific effect on dl but not tl particles,
both particles were treated with an ascites preparation of
mAb 8H2 which had been shown to be directed against
an epitope on VP6 (Ginn et al., 1992). Incubation with
mAb 8H2 neutralized the residual infectivity of dl parti-
cles but had no effect on the infectivity of tl particles
(Table 2). This result indicated that the residual infectivity
in the dl EDIM preparation was due to particles that were
specifically neutralized by anti-VP6 antibody and, there-
fore, was not due to fully encapsidated tl particles.
Protection following intramuscular immunization
Four weeks after the second immunization, mice were
orally challenged with EDIM to determine the level of
protection after i.m. immunization. Mice immunized with
any of the viral particle preparations were significantly
protected as compared to the control (unimmunized)
mice based on the mean days of viral shedding and the
mean quantity of virus shed per mouse (Table 3). Protec-
tion was even found in mice inoculated with dl particles
where no neutralizing antibody was generated. Inclusion
of QS-21 had dramatic effects on the levels of protection
achieved with all three virus preparations. Complete pro-
tection was obtained with infectious tl particles, nearly
complete protection was stimulated by inactivated tl par-
ticles (only one mouse shed low amounts of rotavirus for
3 days), and only three of the six mice shed rotavirus for
2–4 days in mice immunized with dl particles containing
QS-21. When only the mean quantity of virus shed was
compared, infectious tl particles without adjuvant stimu-
lated significantly (P , 0.001) greater protection than
either inactivated tl particles or dl particles. Inactivated tl
particles also provided greater protection than dl parti-
cles (P 5 0.05). It should be noted that inclusion of QS-21
with the dl particles stimulated significantly (P 5 0.02)
TABLE 2
Effect of mAb 8H2 on the Infectivities of dl
and tl Particle Preparationsa
Treatment
Recoverable infectious virus
(FFU/ml)
dl particles tl particles
None 2.9 3 103 2.0 3 103
102 dilution of 8H2 ,3 3 101 1.9 3 103
103 dilution of 8H2 ,3 3 101 1.3 3 103
104 dilution of 8H2 1.6 3 103 1.5 3 103
aPurified preparations of dl and tl EDIM particles were appropriately
diluted and incubated (30 min, 37°C) with an equal volume of mouse
ascites fluid containing mAb 8H2 diluted between 100- and 10,000-fold.
Recoverable infectivities (FFU/ml) were then determined and compared
to those obtained without mAb treatment.
TABLE 3
Shedding of Rotavirus Antigen after EDIM Challengea
Group N
Number
shedding
EDIM
Mean days of
viral
shedding b
Mean quantity
of antigen
shedc
Unimmunized control 6 6 6.8 1.68
Triple-layered EDIM 6 5 3.1d 0.28d,e
Triple-layered EDIM 1QS-21 6 0 0d,f 0d,f
Inactivated triple-layered EDIM 6 5 3.8d 0.67d,g
Inactivated triple-layered EDIM 1QS-21 6 1 0.5d,f 0.02d,f
Inactivated double-layered EDIM 6 6 4.5d 1.17h
Inactivated double-layered EDIM 1QS-21 6 3 1.7d,i 0.13d,f
a Mice were challenged with 4 3 104 FFU of EDIM. Stools were collected from each mouse for 10 days and tested for the presence of rotavirus antigen.
b Defined by the total number of days shedding per animal per group.
c Quantity defined by average A490 values above background for every mouse on each of the 10 days after challenge as determined by ELISA.
d Significantly (P , 0.001) less than unimmunized control group.
e Significantly (P , 0.001) less than group receiving inactivated tl or dl particles.
f Significantly (P , 0.001) less than group without QS-21.
g Significantly (P 5 0.05) less than group receiving dl particles.
h Significantly (P , 0.01) less than unimmunized control group.
i Significantly (P , 0.01) less than group without QS-21.
161PROTECTION AFTER i.m. IMMUNIZATION WITH ROTAVIRUS AND QS-21
better protection than was obtained with inactivated tl
particles without adjuvant.
Rotavirus antibody responses after challenge
To determine the effects of immunization on post-
challenge antibody titers, serum and stool specimens
collected 21 days after EDIM challenge were analyzed
for rotavirus antibody. All unimmunized mice developed
large serum rotavirus IgG responses, but the immunized
animals all had extremely high IgG titers before chal-
lenge, and even those that shed rotavirus after challenge
developed insignificant (i.e. ,fourfold) rises in this anti-
body (Tables 1 and 4). In contrast, there was excellent
agreement between shedding in immunized mice follow-
ing challenge and significant ($fourfold) increases in
both serum and stool rotavirus IgA titers; i.e., only one
immunized mouse that failed to shed virus developed a
significant stool rotavirus IgA response, and one immu-
nized mouse that shed virus failed to develop a fourfold
increase in stool rotavirus IgA. It was of interest to note
that even though mice immunized without QS-21 devel-
oped no detectable stool rotavirus IgA, these mice were
apparently primed to produce this antibody because two
of the three groups developed significantly (P # .01)
higher titers following challenge than the unimmunized
group (Table 4).
DISCUSSION
Rotavirus vaccine candidates that have been evalu-
ated in human trials have all been live, attenuated virus
strains that are delivered orally to mimic natural infec-
tion. The protection provided has been inconsistent,
even against severe disease. Parenteral rotavirus vac-
cines were initially discounted because rotavirus is a
disease of the intestinal mucosa, and intestinal immune
responses, which develop primarily after antigen expo-
sure to mucosal lymphoid tissues, were believed to be
required for protection. This was supported by studies in
lambs (Snodgrass and Wells, 1976) and mice (Offit and
Clark, 1985) which indicated that intestinal, but not cir-
culating rotavirus antibody, was protective against rota-
virus disease. We subsequently reported, however, that
intraperitoneal immunization with infectious or UV inac-
tivated rotaviruses provided good protection against ro-
tavirus infection in adult mice (McNeal et al., 1992).
Conner et al. (1993) also found that intramuscular immu-
nization of rabbits with infectious or inactivated simian
rotavirus protected against subsequent rabbit rotavirus
infection. Therefore, parenteral immunization has be-
come recognized as a possible supplement or alterna-
tive to oral immunization.
Almost all parenteral vaccines are delivered by intra-
muscular inoculation, a route found to provide only par-
tial protection of mice against murine rotavirus infection
in the absence of adjuvant. We, therefore, determined
whether this protection could be significantly augmented
if adjuvant was included in the immunization protocol.
The adjuvant chosen was QS-21 because of its low
toxicity and established ability to enhance both antibody
and cell mediated immune responses.
Mice immunized by two intramuscular injections with
purified, infectious or inactivated tl murine rotavirus
(EDIM) particles or dl particles lacking outer capsid pro-
teins VP4 and VP7 shed less virus than naive mice when
TABLE 4
Geometric Mean Titers of Postchallenge Rotavirus Antibodies in Mice That Shed EDIMa
Group
Number
that shed
EDIM
Serum IgG
(range)
Serum IgA
(range)
Stool IgA
(range)
Unimmunized control 6 125,866 7,793 1,442
(98,477–155,806) (4,950–13,814) (993–1,963)
Triple-layered EDIM 5 1,810,991b 42,560b 3,699c
(1,245,600–2,592,000) (32,765–53,022) (2,433–6,356)
Triple-layered EDIM 1QS-21 0 — — —
Inactivated triple-layered EDIM 5 1,836,137b 65,580b 4,038
(1,554,800–1,989,300) (47,562–82,692) (512–17,669)
Inactivated triple-layered EDIM 1QS-21 1 9,502,000 50,083 7,521
Inactivated double-layered EDIM 6 1,842,466b 32,236b 3,042d
(1,729,000–2,079,000) (20,403–56,086) (1,501–4,629)
Inactivated double-layered EDIM 1QS-21 3 7,861,457b 17,952b 2,688
(7,624,000–8,300,000) (16,981–19,355) (961–4,559
a Stool and blood specimens were collected 21 days after challenge with EDIM. All groups contained 6 mice. Values are the GMT of only those
animals that shed detectable levels of antigen.
b Significantly (P , 0.001) greater than unimmunized control group.
c Significantly (P , 0.002) greater than unimmunized control group.
d Significantly (P , 0.01) greater than unimmunized control group.
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orally challenged with EDIM four weeks after the second
immunization. Addition of QS-21 to the immunization reg-
imen consistently enhanced this protection irrespective
of which EDIM particles were used as the immunogen.
Intramuscular immunization also consistently induced
large serum rotavirus IgG responses, and inclusion of
QS-21 increased these responses approximately 10-fold.
In spite of these very large responses, however, protec-
tion was only complete in mice immunized with infec-
tious tl particles plus QS-21.
It was previously reported that protection following
oral immunization of mice with live virus correlated with
higher titers of both serum and stool rotavirus IgA (Mc-
Neal et al., 1994; Feng et al., 1994). Following intramus-
cular inoculation with EDIM particles, low levels of se-
rum rotavirus IgA were stimulated by each of the virus
particles, and these increased approximately threefold
when QS-21 was included (P , 0.001 for each group).
Therefore, the increased protection associated with
QS-21 also correlated with small but consistent in-
creases in serum rotavirus IgA. The association, how-
ever, was most dramatic when stool rotavirus IgA titers
were examined. In this case, no responses were found
following immunization in the absence of adjuvant, and
low but consistent stool rotavirus IgA titers were found in
all mice when QS-21 was included with each immuno-
gen. Even with adjuvant, however, these titers were still
approximately 10-fold less than generated by oral immu-
nization with live EDIM (see Tables 1 and 4). Since oral
immunization stimulated long-lasting serum and intesti-
nal rotavirus antibody responses and complete protec-
tion for at least 14 months (McNeal and Ward, 1995), it
would be of interest to determine the duration of both
rotavirus antibody and protection following i.m. immuni-
zation.
Because three types of rotavirus particles were used in
this study, it was of interest to compare the antibody re-
sponses and protection induced by each. The infectious tl
particles stimulated antibody production against both struc-
tural and non-structural rotavirus proteins (see Fig. 2) im-
plying that the virus at least initiated a replication cycle
when injected intramuscularly. However, this did not result
in larger serum rotavirus IgG or IgA titers or more stool
rotavirus IgA but did cause an increased level of neutraliz-
ing antibody to EDIM (see Table 1). The protection provided
by infectious EDIM particles was no greater than with
inactivated EDIM when immunization was performed with-
out adjuvant. Additional mice would be required to deter-
mine whether protection was significantly greater using the
infectious particles in the presence of QS-21. Regardless of
whether or not the infectious particles provided greater
protection than inactivated EDIM, this protection was not
due to intestinal replication. Had this occurred, the rotavirus
IgA responses would have been comparable to those
found after oral inoculation of unimmunized mice with live
EDIM.
The other immunogen examined was dl EDIM parti-
cles lacking the VP4 and VP7 outer capsid proteins.
These particles stimulated comparable titers of serum
rotavirus IgG and IgA, as well as stool rotavirus IgA,
relative to tl particles, probably because the inner capsid
protein VP6 is the dominant immunogen. Since VP4 and
VP7 are the neutralization proteins, however, the dl par-
ticles stimulated no detectable neutralizing antibody.
Likewise, the antibody they stimulated immunoprecipi-
tated only inner capsid proteins (see Fig. 2). Even so,
these particles elicited protection against EDIM, and
when injected i.m. with QS-21, the dl particles provided
significantly (P 5 0.02) greater protection against shed-
ding of EDIM than inactivated tl particles injected without
adjuvant. The lack of dependence on neutralizing anti-
body for protection supports previous conclusions found
with this model, i.e. mice were either orally or intraperi-
toneally immunized with heterotypic rotaviruses, made
no neutralizing antibody to EDIM, and were still signifi-
cantly protected against shedding of EDIM when chal-
lenged (Ward et al., 1992; McNeal et al., 1992). Evidence
that immune responses to neither VP4 nor VP7 are re-
quired for protection is supported by two recent reports.
The first was that virus-like particles lacking these pro-
teins stimulate protection when delivered either orally or
intranasally (O’Neal et al., 1997); the second was that
injection of mice with hybridoma cells that produced IgA
against VP6 protected against rotavirus infection (Burns
et al., 1996). Although these results indicate that neither
VP4 or VP7 are required to stimulate immunity in this
model, protection was consistently enhanced when
these proteins were present. Whether this enhancement
was due to stimulation of neutralizing antibody by
epitopes on these proteins or possibly to production of
other immunological effectors such as non-neutralizing
antibody on cytotoxic T lymphocytes remains to be de-
termined.
A study published over a decade ago reported that
mAbs against VP6 had neutralizing activity against rota-
virus (Sabara et al., 1987). Because VP4 and VP7 are the
recognized rotavirus neutralization proteins, this report
has been largely ignored. The finding of low level, resid-
ual infectivity in the dl particle preparation, however,
suggested the possibility that such particles may be
neutralized by antibody to VP6. To test this possibility, we
attempted to neutralize both tl and dl particles with an
anti-VP6 mAb and found it neutralized only the dl parti-
cles (see Table 2). The conclusions from this observation
are that the infectivity in the dl preparation is due to
particles lacking VP4 and VP7 and that such particles
can be neutralized with an anti-VP6 antibody. The mech-
anism by which this neutralization occurs remains to be
determined.
The powerful adjuvant effects exerted by QS-21 in this
study could be due to a number of mechanisms. Saponin
adjuvants such as QS-21 have been shown to stimulate the
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immune system by increasing both TH1 and TH2 responses
(Karagouni et al., 1990; Bomford et al., 1992; Valensi et al.,
1994; Maloy et al., 1995). Regarding antibody production,
TH1 responses augment IgG2a production while TH2 re-
sponses favor the production of IgG1 and IgA. QS-21 has
been shown to induce the three major subclasses of the
IgG isotype: G1, G2a and G2b (Kensil et al., 1991). Although
intestinal rotavirus IgG has been associated with protection
in rabbits (Conner et al., 1993), we were able to detect only
very low titers (GMT of ,30 units/ml for any mouse group)
of stool rotavirus IgG in mice administered any EDIM par-
ticle, even in association with QS-21. Since inclusion of this
adjuvant increased the levels of serum rotavirus IgG and
protection, it is possible that a mechanism of increased
protection induced by QS-21 in this model was through
stimulation of extremely high titers of serum rotavirus IgG.
Another possible protective mechanism for QS-21 is
stimulation of TH2 responses and, subsequently, rotavi-
rus IgA levels. The effect of QS-21 on IgA was most
pronounced in stool specimens where titers increased
from undetectable (i.e., ,5 units/ml) to as high as 622
units/ml. Because the ratios between these titers and
those of serum rotavirus IgA did not correlate on an
animal-by-animal basis, it appeared that the presence of
rotavirus IgA in stool was not due merely to increased
concentrations of serum rotavirus IgA. To our knowledge,
this is the first direct evidence that QS-21 can induce
intestinal IgA following parenteral immunization. In a
study by Thaper et al. (1991) using ISCOMS containing
saponins, it was shown that a vaginal mucosal response
was induced after i.m. immunization. In addition, studies
by Ahmeida et al. (1992, 1993) showed that influenza
virus given by i.m. inoculation with ISCOMS induced
nasal IgA responses comparable to that found after in-
tranasal immunization with live virus, and the i.m. immu-
nization was as protective as the nasal immunization.
Finally, using a passive protection baboon model,
Snodgrass et al. (1995) reported an increase in rotavirus
IgA, IgG, and neutralizing antibody in milk following in-
tramuscular injection of pregnant females with rotavirus
and ISCOMS suggesting a boosting of a mucosal re-
sponse. Although the components of ISCOMS responsi-
ble for these mucosal immune responses were not iden-
tified, it may have been saponins such as QS-21.
The results presented in this study demonstrate that
active immunity to rotavirus can be obtained following
intramuscular injection with live or inactivated tl EDIM
particles or with dl particles lacking VP4 and VP7. The
addition of the saponin adjuvant QS-21 increased the
level of protection obtained with each viral particle. Since
rotavirus serum IgG and IgA and stool IgA were all
dramatically increased by the addition of QS-21, it cannot
be predicted which, if any, was responsible for the higher
level of protection. If induction of mucosal rotavirus IgA,
which has been found to correlate with protection fol-
lowing oral immunization with live rotavirus, is necessary
for protection, QS-21 acting as an immune modulator
may be an excellent adjuvant to include with other par-
enteral rotavirus vaccines.
MATERIALS AND METHODS
Mice
Female BALB/c mice purchased from Harlan–Spra-
gue–Dawley (Indianapolis, IN) were used at 6 weeks of
age. All animals were found to have no serum rotavirus
IgG or IgA or stool rotavirus IgA as determined by ELISA
(McNeal et al., 1995). Microisolator cages were used to
house the animals during the entire study. Six animals
were used in each group (three/cage). All procedures
were conducted in accordance with protocols approved
by the Children’s Hospital Research Foundation Institu-
tional Animal Care and Use Committee.
Virus and viral particles for immunization
The G3 [P16] EDIM strain of rotavirus used in this
study was adapted to grow in cell culture by passage in
MA104 cells as previously described (Ward et al., 1990).
A preparation of the ninth cell culture passage contain-
ing 2 3 106 FFU per ml was used to orally challenge
mice. The EDIM virus used to generate viral particles for
immunization was a triply plaque picked isolate that had
been passaged a total of 41 times in MA104 cells and
purified by CsCl centrifugation (McNeal et al., 1992). Tl
infectious virus (1.36 g/ml) and dl particles lacking VP4
and VP7 (1.38 g/ml) were collected from the same gradi-
ent. The dl particles were further treated with 10 mM
EDTA and purified a second time in CsCl to ensure
complete removal of VP4 and VP7 proteins. Following
purification, the virus particles were dialyzed against
phosphate-buffered saline containing 20% glycerol and
stored frozen at 270°C. To establish which proteins
were present in the particles, each was analyzed by
SDS–polyacrylamide gel electrophoresis as previously
described (McNeal et al., 1992). Purified tl or dl EDIM
particles were inactivated by UV/psoralen treatment as
described by Groene and Shaw (1992). In short, the
particles were dispensed into 60-mm petri dishes and
psoralen (49-aminomethyltroxsalen HCl; Lee Biomolecu-
lar Research, Inc., San Diego, CA) was added at a con-
centration of 40 mg/ml. The virus was then placed in ice
on a rotating platform at a distance of 10 cm and irradi-
ated with high intensity, longwave length UV light (365
nm, 40 min). Following treatment, the viral titer was
determined by a fluorescent focus assay as previously
described (Knowlton et al., 1991). Although the infectivity
of tl particles containing 8.4 3 108 FFU/ml was reduced
below detectable limits (i.e., 102 FFU/ml) by 20 min of UV
treatment, the irradiation time was extended to 40 min to
ensure that no infectious virus remained.
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Monoclonal antibody (mAb)
Ascites fluid obtained from mice inoculated with a
hybridoma producing mAb 8H2/G5 was used to neutral-
ize purified tl and dl EDIM particles prior to UV/psoralen
treatment using procedures already described (Knowlton
et al., 1991). This mAb was shown to be specific for
rotavirus protein VP6 (Ginn et al., 1992).
Study design
Mice were immunized by i.m. injection with viral par-
ticles including tl infectious virus, tl inactivated virus, or
dl inactivated virus. Each injection was with 50 ml con-
taining 20 mg of viral protein, either with or without 20 mg
of QS-21 (Wyeth-Lederle Vaccines and Pediatrics, Pearl
River, NY), into the thigh muscle of the hind leg. Two
immunizations were given 2 weeks apart beginning on
day 0. Mice were then orally challenged with 4 3 104 FFU
of EDIM 4 weeks after the last injection. Stool specimens
were collected daily for 10 days after challenge and
analyzed for rotavirus antigen. Blood specimens were
collected by retroorbital capillary plexus puncture on day
0, on the day before challenge, and 21 days after chal-
lenge. Stool specimens were also collected at these time
points. These blood and stool specimens were used to
measure rotavirus serum IgA, IgG and neutralizing anti-
body, and rotavirus stool IgA titers.
Detection of rotavirus antigen in stool
Two stool pellets collected into 0.5 ml of Earle’s bal-
anced salt solution (EBSS) on each day following EDIM
challenge were stored frozen (220°C). To test for rota-
virus antigen, the specimens were thawed, homoge-
nized, and analyzed by ELISA as previously described
(McNeal et al., 1994). The quantity of virus shed was
determined by net A490 values (i.e., the average of two
rotavirus negative antibody-coated wells subtracted from
the average of two rotavirus antibody-coated wells). A490
values of $3.0 were assigned values of 4.0 for quantita-
tion purposes. To determine the amount of rotavirus shed
per mouse within a group, the average A490 values above
background were determined for every mouse on each
of the 10 days after EDIM challenge.
Determination of rotavirus antibody titers
Serum rotavirus IgA and IgG and rotavirus stool IgA
were measured by ELISA as previously described (Mc-
Neal et al., 1995). Briefly, EIA plates (Corning Costar Co.,
Cambridge, MA) were coated overnight at 4°C with anti-
rotavirus rabbit IgG. After washing with phosphate buff-
ered saline plus 0.05% Tween 20, EDIM viral lysate and
mock-infected cell lysate were each added to duplicate
wells. Serial 2-fold dilutions of pooled sera from EDIM
infected mice assigned concentrations of 160,000 or
10,000 units/ml of rotavirus IgG or IgA, respectively, were
added to duplicate wells coated with either EDIM-in-
fected or uninfected MA104 cell lysates to generate a
standard curve. Serial 10-fold dilutions of mouse sera to
be tested were also added to duplicate wells of each
lysate. This was followed by sequential addition of biotin-
conjugated goat anti-mouse IgG or IgA (Sigma Chemical
Co., St. Louis, MO), peroxidase-conjugated avidin-biotin
(Vector Laboratories, Burlingame, CA), and o-phenylene-
diamine substrate (Sigma Chemical Co.). Color develop-
ment was stopped after 15 min with 1 M H2SO4 and the
A490 was measured. Titers of rotavirus IgG or IgA, ex-
pressed as units/ml, were determined from the standard
curve generated by subtraction of the average A490 val-
ues of the duplicate cell lysate wells from the average of
the wells coated with EDIM lysate.
For determination of stool rotavirus IgA, two stool pel-
lets were collected into 0.5 ml of EBSS, homogenized,
and centrifuged (1500g, 5 min). Stool rotavirus IgA was
then measured by the method described above.
Neutralizing antibody to EDIM was determined by us-
ing an antigen reduction ELISA assay as described pre-
viously (Knowlton et al., 1991).
Immunoprecipitation of viral proteins
Pooled sera from mice inoculated with tl or dl particles
(live or inactivated) were used to immunoprecipitate 35S-
labeled EDIM to identify immunogenic EDIM proteins.
The procedures for radiolabeling EDIM, immunoprecipi-
tation, and SDS–polyacrylamide gel electrophoresis
have been previously described (McNeal et al., 1992).
Statistical analyses
Differences in the mean quantity of rotavirus antigen
shed per mouse and the mean number of days shedding
between groups were determined by Student’s t test.
Differences in geometric mean titers of rotavirus anti-
body between groups of mice were evaluated by this
same statistical test.
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